|
See related Fasturtec powd for inj information |
|
|
|
Manufacturer |
sanofi-aventis |
|
Distributor |
Hong Kong: LF Asia |
|
Contents |
Rasburicase |
|
Indications |
Treatment & prophylaxis of acute hyperuricaemia, in order to prevent acute renal failure, in patients w/ haematologic malignancy w/ a high tumour burden & at risk of a rapid tumour lysis or shrinkage at initiation of chemotherapy.
Click to view Fasturtec detailed prescribing infomation |
|
Dosage |
0.2 mg/kg/day as a once daily 30 min IV infusion for 5-7 days.
Click to view Fasturtec detailed prescribing infomation |
|
Overdosage |
View Fasturtec overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
G6PD deficiency & other cellular metabolic disorders known to cause haemolytic anaemia.
Click to view Fasturtec detailed prescribing infomation |
|
Special Precautions |
Monitor closely for onset of allergic-type undesirable effects, esp allergic skin reaction or bronchospasm. History of atopic allergies. Pregnancy & lactation.
Click to view Fasturtec detailed prescribing infomation |
|
Adverse Drug Reactions |
Fever, vomiting, nausea. Uncommonly, diarrhoea, headache, allergic reactions including bronchospasm. Methaemoglobinaemia.
View ADR Monitoring Form |
|
Drug Interactions |
[Click for Fasturtec detailed prescribing infomation]
View more drug interactions with Fasturtec |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Storage |
View Fasturtec storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Fasturtec description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Fasturtec mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
ATC Classification |
V03AF07 - rasburicase ; Belongs to the class of detoxifying agents used in antineoplastic treatment. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Fasturtec powder for injection |
|
|
|
Manufacturer: |
sanofi-aventis |
|
Distributor: |
Hong Kong: LF Asia
|
|
|
|
